Jonathan Schroeder
Internal Medicine · Baton Rouge, LANPI 1376802595
Payments from drug & device makers
Across 284 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$776
- Johnson & Johnson$543
- EMD Serono, Inc.$238
- Merck$232
- GSK$209
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,94397%
- Education$1323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 105 | $1,740 |
| Gilead | 39 | $776 |
| Johnson & Johnson(2 entities) | 37 | $543 |
| EMD Serono, Inc. | 11 | $238 |
| Merck | 13 | $232 |
| GSK | 11 | $209 |
| Lilly USA, LLC | 10 | $160 |
| Bayer | 5 | $109 |
| Theratechnologies Inc. | 6 | $108 |
| Sumitomo Pharma America, Inc. | 6 | $108 |
| Novo Nordisk | 6 | $106 |
| Janssen Products, LP | 2 | $103 |
| Janssen Scientific Affairs, LLC | 4 | $96 |
| Pfizer | 5 | $90 |
| Dexcom, Inc. | 4 | $90 |
| Boehringer Ingelheim | 4 | $73 |
| AstraZeneca | 4 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| AbbVie | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $17 |
| Novartis | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Exact Sciences | 1 | $14 |
How this compares
$5,075 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 809 | $3,080,327 |
| DovatoDolutegravir Sodium/Lamivudine | 216 | $620,764 |
| TivicayDolutegravir Sodium | 204 | $531,895 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 84 | $320,779 |
| JulucaDolutegravir/Rilpivirine | 64 | $215,277 |
| DescovyEmtricitabine/Tenofov Alafenam | 93 | $199,701 |
| Pyrimethamine | 13 | $115,659 |
| PrezcobixDarunavir/Cobicistat | 44 | $106,431 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 22 | $97,380 |
| OzempicSemaglutide | 73 | $78,709 |
| MounjaroTirzepatide | 67 | $78,547 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 22 | $74,928 |
| JardianceEmpagliflozin | 74 | $61,386 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $35,757 |
| TrulicityDulaglutide | 26 | $34,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $776 | $3,280,028902 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Juluca | $1,740 | $1,688,716568 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi | $160 | $118,882104 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $543 | $113,89858 claims |
| Novo NordiskOzempic, Rybelsus | $106 | $97,75892 claims |
| Janssen Products, LPSymtuza | $103 | $97,38022 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $73 | $69,29091 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $209 | $44,52095 claims |
| PfizerEliquis | $90 | $31,33740 claims |
| MerckPifeltro | $232 | $19,47311 claims |
| BayerKerendia | $109 | $18,91623 claims |
| NovartisEntresto | $17 | $12,74716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Baton Rouge
- Katherine PearceBaton Rouge$12M
- Donna RyanBaton Rouge$991K
- Gertrude Chimeka AnyanwokeBaton Rouge$611K
- Deepesh PatelBaton Rouge$304K
- John SchwabBaton Rouge$122K
- Barret MurphyBaton Rouge$43K
- Brian GremillionBaton Rouge$27K
- Raoul ManalacBaton Rouge$27K
- Bradley MeekBaton Rouge$20K
- William SmithNew Orleans$50.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.